Several laboratories have reported that cancer cells lacking wild type p53 are significantly more sensitive to PLK1 inhibition as compared with cells retaining wild type p53 function26,31–35, suggesting that p53 can offer protection against PLK1 inhibitors. Here, TP53 is linked to cancer.